← All trials
NCT04892641
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2021
- Primary completion
- Nov 30, 2021
- Completion date
- Feb 28, 2022
- First posted
- May 19, 2021
- Last posted
- Jun 4, 2021
- Enrollment
- 56
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AN2 Therapeutics, IncLead sponsor
- CMAX Clinical ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.